Sodium valproate in the treatment of levodopa-induced dyskinesia.

Publisher Website
Google Scholar
Abstract
The effect of sodium valproate 1200 mg daily on the disability of parkinsonism and on L-dopa-induced dyskinesias was assessed in a double-blind crossover trial with matched placebo in 12 patients with Parkinson''s disease. No objective change in the severity of parkinsonism or dyskinesias was noted. Patients (6 of 9) who completed the trial noted a slight to moderate improvement in their dyskinesias with no change in their parkinsonism. Excess salivation improved in 4 subjects on sodium valproate.